Gilead Sciences and Lakefront Biotherapeutics have acquired Ouro Medicines and its investigational therapy, gamgertamig, for cold agglutinin disease (CAD) and other forms of autoimmune hemolytic anemia (AIHA). Gamgertamig is also being developed as a treatment for several other autoimmune diseases. Under the deal, valued at up to $2.175 billion,…
Discussion
I looked around the yard in dismay after walking through the rotting wooden door of our screened-in back porch to assess the challenges before me. The backyard of our Alabama home didn’t look like this when my husband, Mike, and I left it last summer for our work in Indonesia.
A 70-year-old woman with cold agglutinin disease (CAD) avoided disease-related complications from surgery related to a heart condition, in part because she took Enjaymo (sutimlimab-jome) before the operation for a heart condition, a case study from the U.S. reported. In addition to giving the woman Enjaymo, an approved…
Discussion
I made a decision on June 5, 1972, that has affected the rest of my life. Actually, that one decision rippled outward and affected many people worldwide, including my children, extended family, and students from six continents. On that day, my husband, Mike, and I stood before our families and…
Discussion
I left the doctor’s office feeling deeply conflicted, wondering whether I had made the right decision. I didn’t even look at the orders for a blood test before stuffing them into the back of my car seat. I had reached the end of my tolerance. I had just said no…
Cold agglutinin disease (CAD) is a rare disorder in which the immune system mistakenly attacks red blood cells, resulting in anemia.
CAD is characterized by autoantibodies, called cold agglutinins, binding to and activating the destruction of red blood cells when exposed to cold temperatures.
Symptoms of CAD include fatigue, Raynaud’s syndrome, joint pain, jaundice or skin discoloration, and heart problems. These symptoms can worsen with more cold exposure.
Get regular updates to your inbox.
